Janssen Research & Development, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$22Mgeneral payments (2019-2025)
$3.3Mresearch payments (2019-2025)
6,710clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Tremfya $637K associated (2023-2025)
- Carvykti $346K associated (2023-2025)
- Darzalex $303K associated (2023-2025)
- Erleada $261K associated (2023-2025)
- Tecvayli $249K associated (2023-2025)
- Stelara $57K associated (2023-2025)
- Invokana $26K associated (2023-2025)
- Xarelto $23K associated (2023-2025)
- Simponi $19K associated (2023-2025)
- Remicade $16K associated (2023-2025)
- Invega Trinza $8,600 associated (2023-2025)
- Spravato $6,627 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Chaitanya Divgi | New York, NY | Nuclear Medicine | $1,142,288.09 |
| Barry Gertz | Rahway, NJ | Endocrinology, Diabetes & Metabolism | $900,792.87 |
| Lori Cox | New Brunswick, NJ | Rheumatology | $441,467.50 |
| Timothy Albertson | Sacramento, CA | Critical Care Medicine (Internal Medicine) | $411,750.00 |
| James Streisand | Cambridge, MA | Anesthesiology | $378,400.00 |
| S Claiborne Johnston | San Francisco, CA | Neurology (Psychiatry & Neurology) | $361,001.40 |
| Debra Cipriani | Jenkintown, PA | Neonatal-Perinatal Medicine | $346,258.39 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $332,275.00 |
| Asha Shah | Tampa, FL | Dermatology | $332,048.69 |
| Marilyn Pike | Boston, MA | Rheumatology | $330,998.71 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.